Zymeworks Inc. announced in connection with the Restructuring, effective January 19, 2022, the Company terminated the employment of Dr. Anthony Polverino, Executive Vice President, Early Development & Chief Scientific Officer and in connection with the Restructuring, effective January 19, 2022, the Company terminated the employment of Ms. Kathryn O'Driscoll, Chief People Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.12 USD | +0.66% | +6.29% | -12.22% |
05-02 | Transcript : Zymeworks Inc., Q1 2024 Earnings Call, May 02, 2024 | |
05-02 | Zymeworks Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.22% | 650M | |
+10.44% | 107B | |
+0.82% | 106B | |
+6.72% | 23.47B | |
-13.89% | 21.9B | |
-6.64% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Zymeworks Inc. Announces Management Changes